Patient Advocacy SymposiumJune 9, 2008

Axel Grothey, MDGroup Vice Chair

CP1223393-2

3 Trial design and conduct• To improve clinical trial design and conduct

1 Improved therapeutics• To improve the duration and quality of life

of cancer patients

Specific Aims

22 Translational research• To improve the understanding of cancer biology

and the biological consequences of treatment

4 Cancer prevention and control• To provide an infrastructure for studies of cancer

prevention and symptom management

CP1223393-3

IdeaGenerators

NCCTGPrograms

NCCTGLeadership

NCCTG Organizational Overview

MCCC and other academic centers

Cooperativegroups

Industry

NCI

CommunityOncologists

CommunityOncologyPrograms

CommunityOncologyPrograms

CP1223393-4

Community-Based Partnership

NCCTG in 1977

WA

ORID

MT

Saskatchewan

WY

UTNV

CA

AZ NM

CO

NE

SD

NDMN

MOKS

FL

NC

MI

KY

OH

VA

PA

NY

ME

NHVT

IAIL

WI

Ontario

Mexico

GA

TX LA

ARAL

TN

MS

OK SC

IN

WV

AK

MDDE

NJCT

RI

MA

PR

HI

DC

CP1223393-6

The 43 NCCTG Memberships Are The 43 NCCTG Memberships Are Headquartered in 28 States & CanadaHeadquartered in 28 States & Canada

AK

HI

PR

WA

ORID

MT

Saskatchewan

WY

UTNV

CA

AZ NM

CO

NE

SD

NDMN

MOKS

FL

NC

MI

KYWV VA

PA

NY

MDDE

NJCT

RI

MA

ME

NHVT

IAIL

WI

DC

GA

TX LA

ARAL

TN

MS

OK SC

IN OH

CP1223393-7

NCCTG has >340 treating locations in 33 NCCTG has >340 treating locations in 33 states as well as Canada & Puerto Ricostates as well as Canada & Puerto Rico(Pending/newly approved treating locations in red states)

AK

WA

ORID

MT

Saskatchewan

WY

UTNV

CA

AZ NM

CO

NE

SD

NDMN

MOKS

FL

NC

MI

KY

OH

VA

PA

NY

MDDE

NJCT

RI

MA

ME

NHVT

IA

19

12

5

6

3

IL

WI

DC

37

25

17

45

2

425

2

4

HI

GA10

TX LA

ARAL

TN

MS

OK

2 2

6

1

16

SC3

IN

1

14

916 WV

1

PR

21

1

1

2

2

2

2

4

AK

WA

ORID

MT

Saskatchewan

WY

UTNV

CA

AZ NM

CO

NE

SD

NDMN

MOKS

FL

NC

MI

KY

OH

VA

PA

NY

MDDE

NJCT

RI

MA

ME

NHVT

IA

19

12

5

6

3

IL

WI

DC

37

25

17

45

2

425

2

4

HI

GA10

TX LA

ARAL

TN

MS

OK

2 2

6

1

16

SC3

IN

1

14

916 WV

1

PR

21

1

1

2

2

2

2

4

AK

WA

ORID

MT

Saskatchewan

WY

UTNV

CA

AZ NM

CO

NE

SD

NDMN

MOKS

FL

NC

MI

KY

OH

VA

PA

NY

MDDE

NJCT

RI

MA

ME

NHVT

IA

19

12

5

6

3

IL

WI

DC

37

25

17

45

2

425

2

4

HI

GA10

TX LA

ARAL

TN

MS

OK

2 2

6

1

16

SC3

IN

1

14

916 WV

1

PR

21

1

1

2

2

2

2

4

AK

WA

ORID

MT

Saskatchewan

WY

UTNV

CA

AZ NM

CO

NE

SD

NDMN

MOKS

FL

NC

MI

KY

OH

VA

PA

NY

MDDE

NJCT

RI

MA

ME

NHVT

IA

19

12

5

6

3

IL

WI

DC

37

25

17

45

2

425

2

4

HI

GA10

TX LA

ARAL

TN

MS

OK

2 2

6

1

16

SC3

IN

1

14

916 WV

1

PR

21

1

1

2

2

2

2

4

8

New members since last meeting

• Keith Lanier, MD – Columbia River CCOP, Portland, OR

• Meera Ravidranathan, MD – New Mexico MBCCOP, Richmond, VA

• Mary Helen Hackney, MD – Virginia Commonwealth MBCCOP, Richmond, VA

• Marianne Lange, MD – Grand Rapids Clinical Oncology Program, Grand Rapids, MI

• Jacqueline Vuky, MD – Virginia Mason Research Center CCOP, Seattle, WA

CP1223393-9

Membership and Governance

Membership• 32 CCOPs• 11 Non-CCOPs

Executive CommitteeMembership PI and Modality Co-Chairs• Chair: J. Kugler – Peoria, IL• Vice Chair: P. Stella – Ann Arbor,

MI

CP1223393-10

Membership and Governance

Membership• 32 CCOPs• 11 Non-CCOPs

Executive CommitteeMembership PI and Modality Co-Chairs• Chair: J. Kugler – Peoria, IL• Vice Chair: P. Stella – Ann Arbor,

MI

CP1223393-11

Community Member Involvement

• Co-Chairs of scientific committees

• Participate in protocol review

• Co-chairs of protocols

• Audits

• Patient Advocate Network

CP1223393-12

Community Accrualand Data Quality

• 78% of NCCTG accrual fromthe community

• Every NCCTG coordinated trial in last grant period opened and accrued patients at a community site

• Since 2003: 60 audits; 1 unacceptable

13

ASCO Community Participation Award Nominees 2008

Preston D. Steen, M.D.

MeritCare Hospital CCOP

Fargo, ND

Roscoe F. Morton, M.D.Iowa Oncology Research

Association CCOPDes Moines, IA

CP1223393-14

NCCTG Organizational Overview

NCCTGLeadership

IdeaGenerators

Clinical data

Biospecimens

MCCC and other academic centers

Cooperativegroups

Industry

NCI

CommunityOncologists

CommunityOncologyPrograms

CommunityOncologyPrograms

CP1223393-15

Mayo Clinic Cancer Center

• Leadership

• Integrated systems

• Financial support

CP1223393-16

Mayo Clinic Cancer Center

• Leadership

• Integrated systems

• Financial support

CP1223393-17

Mayo Clinic Cancer Center

• Leadership

• Integrated systems

• Financial support

NCCTG Committees

Discipline-Oriented Scientific

• Cancer Control

• Novel Therapeutics

• Quality of Life

Modality

• Pathology

• Radiation Oncology

• Surgery

Core Function

• Audit

• Cancer Health Disparity

• Oncology Nursing

• Clinical Research Assoc Board

• Patient Advocates

Statistics and Data Center

• Biostatistics

Advisory

• Translational Research Coord

Loprinzi Martenson Jatoi Brown

Goetz Erlichman Adjei Galanis

Halyard Grothey Jatoi Brown

Visscher Smyrk Aubry Scheithauer

Halyard Martenson Schild Brown

Pockaj Cima Nichols New

Perotti Pearson Garces Leitch

Greder Finck DeKrey Kowbell

Mahacek Barnick Rogers Dillavou

Smith DeLucca Keller Buckmeier

Dueck Sargent Mandrekar Ballman

Goetz Sinicrope Molina Jenkins

Breast Gastrointestinal Lung Neuro-oncology

Disease Specific

LIAISONS

CP1223393-19

Protocol Activity2001-2005

NCCTG-led 61• Actively accruing 28• In development 24• Closed, in follow up 103

NCCTG-endorsed 65

CP1223393-20

Accrual to NCCTG Trials2001-2005

NCCTG-led• Patients

8,631• NCCTG member accrual

3,952

NCCTG-endorsed• NCCTG member accrual

3,307

CP1223393-21

NCCTG Manuscripts – 2001-2006(Published and Accepted)

Total 217

• NEJM 5

• JNCI 4

• JCO 60

CP1223393-22

Abstracts and PresentationsASCO 2001-2007

Total 229

• Plenary 2

• Oral 63

• Poster discussion 66

• Poster 80

• Publication 18

CP1223393-23

ASCO Abstracts 2008

Oral

Poster Discussion

Poster

Publication

Pending

10 9

14 11

17 16

6 6

2 0

49 42

Numbers in red are NCCTG-Led

24

ASCO Abstracts 2008

BrainBreastCancer ControlGILungNovel TherapeuticsQOLStatistical Methods

Numbers in red are NCCTG-Led Studies

(4 ASCO GI)

3 29 67 715 136 53 34 42 249 42

CP1223393-25

Aim 1 Improved Therapeutics Future Plans

THEPATIENT

Targeted

therapiesChemo-

therapy

Radiation Surgery

Measureof Success

Measureof Success

Survival

AND

Quality of Life

CP1223393-26

Aim 2 Translational Research Future Plans

THE PATIENT

PatientBiology

Pharmaco-genomics

Immunology

TumorBiology

Tumortissue

biomarkers

CP1223393-27

NCCTGHigh-quality science

• Practice-changing therapies• Clinically meaningful translational results• Influential methodologic analyses• Active cancer control research

Committed to collaboration• Community oncology and

academic centers